Evidence map›Paper›PMID 36915247›Full record

ArticleCancer research and treatment2023

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer.

Dae-Won Lee, Yoojoo Lim, Hwang-Phill Kim, Su Yeon Kim, Hanseong Roh, Jun-Kyu Kang, Kyung-Hun Lee, Min Jung Kim, Seung-Bum Ryoo, Ji Won Park and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dae-Won LeeDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Yoojoo LimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Hwang-Phill KimIMBdx, Inc., Seoul, Korea.
Su Yeon KimIMBdx, Inc., Seoul, Korea.
Hanseong RohIMBdx, Inc., Seoul, Korea.
Jun-Kyu KangIMBdx, Inc., Seoul, Korea.
Kyung-Hun LeeDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Min Jung KimDepartment of Surgery, Seoul National University Hospital, Seoul, Korea.
Seung-Bum RyooDepartment of Surgery, Seoul National University Hospital, Seoul, Korea.
Ji Won ParkDepartment of Surgery, Seoul National University Hospital, Seoul, Korea.
Seung-Yong JeongDepartment of Surgery, Seoul National University Hospital, Seoul, Korea.
Kyu Joo ParkDepartment of Surgery, Seoul National University Hospital, Seoul, Korea.
Gyeong Hoon KangDepartment of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Sae-Won HanDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Tae-You KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

Funding

Korea Health Industry Development InstituteMinistry of Health and Welfare HI14C1277
6 · The paper itself

Abstract

purposeCirculating tumor DNA (ctDNA) is emerging as a valuable non-invasive tool to identify tumor heterogeneity and tumor burden. This study investigated ctDNA dynamics in metastatic colorectal cancer patients treated with regorafenib. Materials and Methods: In this prospective biomarker study, plasma cell-free DNA (cfDNA) samples obtained at baseline, at the first response evaluation after 2 cycles of treatment, and at the time of progressive disease were sequenced using a targeted next-generation sequencing platform which included 106 genes.

resultsA total of 285 blood samples from 110 patients were analyzed. Higher baseline cfDNA concentration was associated with worse progression-free survival (PFS) and overall survival (OS). After 2 cycles of treatment, variant allele frequency (VAF) in the majority of ctDNA mutations decreased with a mean relative change of -31.6%. Decreases in the VAF of TP53, APC, TCF7L2, and ROS1 after 2 cycles of regorafenib were associated with longer PFS. We used the sum of VAF at each time point as a surrogate for the overall ctDNA burden. A reduction in sum (VAF) of ≥ 50% after 2 cycles was associated with longer PFS (6.1 vs. 2.7 months, p=0.002), OS (11.3 vs. 5.9 months, p=0.001), and higher disease control rate (86.3% vs. 51.1%, p < 0.001). VAF of the majority of the ctDNA mutations increased at the time of disease progression, and VAF of BRAF increased markedly.

conclusionReduction in ctDNA burden as estimated by sum (VAF) could be used to predict treatment outcome of regorafenib.

Indexed as

Cell-Free Nucleic AcidsCirculating Tumor DNAColonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsBiomarkers, TumorHumansMutationPhenylurea CompoundsProtein-Tyrosine KinasesProto-Oncogene ProteinsPyridinesTreatment OutcomeBiomarkers, TumorCell-Free Nucleic AcidsCirculating Tumor DNAPhenylurea CompoundsProtein-Tyrosine KinasesProto-Oncogene ProteinsPyridinesregorafenibColorectal neoplasmsctDNALiquid biopsyRegorafenib

Identifiers

PMID36915247
PMCPMC10372591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.